CRIZANLIZUMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 11:38:21 GMT 2023` Edited by `admin` on `Sat Dec 16 11:38:21 GMT 2023`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG2
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	L7451S9126
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

CRIZANLIZUMAB

Official Name

English

CRIZANLIZUMAB [MI]

Common Name

English

SEG-101

Code

English

crizanlizumab [INN]

Common Name

English

IMMUNOGLOBULIN G2, ANTI-(HUMAN P-SELECTIN) (HUMAN-MUS MUSCULUS MONOCLONAL SELG1 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SELG1 LIGHT CHAIN, DIMER

Systematic Name

English

IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS P-SELECTIN GLYCOPROTEIN LIGAND (CD62 ANTIGEN))HUMANIZED MONOCLONAL ANTIBODY.GAMMA.2 HEAVY CHAIN (1-448) (HUMANIZED VH (HOMO SAPIENS IGHV1-8*01 (82%) (IGHD)-IGHJ4*01) (8.8.15) (1-122) -HOMO SAPIENS IGHG2*02 (CH2

Systematic Name

English

NVP-LXI262

Code

English

NVP-LXI-262

Code

English

Crizanlizumab [WHO-DD]

Common Name

English

SEL-G1

Code

English

CRIZANLIZUMAB [USAN]

Common Name

English

SEG101

Code

English

SELG1

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C78275

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

FDA ORPHAN DRUG

259708

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

Code System Code Type Description

DRUG CENTRAL

5365

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

SMS_ID

100000174637

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

USAN

FG-105

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

RXCUI

2262279

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

RXCUI

2262421

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

ALTERNATIVE

CAS

1690318-25-2

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

NCI_THESAURUS

C133543

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

INN

10316

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

DAILYMED

L7451S9126

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

LACTMED

Crizanlizumab

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

WIKIPEDIA

Crizanlizumab

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

DRUG BANK

DB15271

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

MERCK INDEX

m12180

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

FDA UNII

L7451S9126

Created by admin on Sat Dec 16 11:38:21 GMT 2023 , Edited by admin on Sat Dec 16 11:38:21 GMT 2023

PRIMARY

From	To
1_22	1_96
1_149	1_205
1_262	1_322
1_368	1_426
2_22	2_96
2_149	2_205
2_262	2_322
2_368	2_426
3_23	3_92
3_138	3_198
4_23	4_92
4_138	4_198
1_136	3_218
2_136	4_218
1_224	2_224
1_225	2_225
1_228	2_228
1_231	2_231

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_298
N	2_298

Related Record Type Details


					Q7C1CQ328P

TARGET -> INHIBITOR

CRIZANLIZUMAB-TMCA

SUB_CONCEPT->SUBSTANCE

Amount:

Related Record Type Details


					L7451S9126

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL